Precision Biosciences SEC Filings

Precision BioSciences director Stanley R. Frankel reported buying 2,700 shares of the company’s common stock on December 16, 2025 at a price of $4.70 per share. This insider purchase increased his directly held stake to 19,478 shares. The transaction was reported as a routine filing by a single reporting person.

Precision BioSciences director Melinda Brown reported buying 1,381 shares of the company’s common stock on 12/15/2025 at a weighted average price of $4.97 per share. Following this open-market purchase, she beneficially owns 23,346 shares held directly. The shares were acquired in multiple transactions at prices ranging from $4.95 to $5.01, and the reporting person has undertaken to provide full trade-level pricing details upon request.

Precision BioSciences announced an underwritten offering of 10,815,000 shares of common stock with accompanying one-half warrants to purchase up to 5,407,500 shares at a combined price of $6.14. In lieu of common stock for certain investors, the company is also selling pre-funded warrants to purchase up to 1,400,000 shares with accompanying one-half warrants to purchase up to 700,000 shares at a combined price of $6.139995. Each whole warrant is immediately exercisable at $7.25 per share and expires five years from issuance.

The company estimates net proceeds of approximately $70.0 million, excluding any proceeds from warrant exercises. Funds are intended for ongoing and planned research and development, working capital, and general corporate purposes. The securities are offered off an effective Form S-3 shelf, with closing expected on November 12, 2025, subject to customary conditions. Beneficial ownership limits include 4.99% (or 9.99% at holder election) and 19.99% thresholds as outlined.

Precision BioSciences (DTIL) launched an underwritten primary offering of 10,815,000 shares of common stock with accompanying warrants to purchase 5,407,500 shares, plus pre-funded warrants to purchase up to 1,400,000 shares with accompanying warrants. In total, warrants in this financing cover up to 6,107,500 shares. The combined price is $6.14 per common share plus one-half warrant, and $6.139995 per pre-funded warrant plus one-half warrant. Each warrant is immediately exercisable at $7.25 per share and expires five years from issuance.

The pricing table shows a total offering amount of $75,000,093, underwriting discount of $4,500,006, and proceeds before expenses of $70,500,087. The company estimates net proceeds of approximately $70.0 million, intended for ongoing and planned research and development, working capital, and general corporate purposes. The company does not intend to list the warrants or pre-funded warrants. Shares outstanding are expected to be 22,897,665 after the offering, based on 12,082,665 outstanding as of September 30, 2025.

Precision BioSciences furnished an update on its ELIMINATE-B Phase 1 study of PBGENE-HBV and announced related webcast details. As of October 31, 2025, nine evaluable patients were dosed across three ascending cohorts (0.2, 0.4, 0.8 mg/kg), with 22 total administrations. All treated patients showed measurable HBsAg declines across dose levels, with durability improving at higher doses.

Cohort 1 included a patient with a durable ~50% HBsAg reduction at 9 months. In Cohort 2, durable declines were maintained after the first administration and deepened after subsequent doses, reaching up to 66%. In Cohort 3, all patients showed early HBsAg reductions; one had a deepening response to two doses with a 64% decline, and levels fell as low as 188 IU/mL. A paired liver biopsy confirmed ARCUS-mediated editing of HBV DNA, supporting the therapy’s mechanism. PBGENE-HBV was well tolerated with no dose-limiting toxicities; transient infusion reactions and liver enzyme elevations resolved, including one reversible Grade 3 AST. The company plans to complete Cohort 3 and finalize in Q1 2026, then move to Part 2 to evaluate an optimized regimen.

Precision BioSciences (DTIL)November 2, 2025, 3,605 RSUs vested and settled, resulting in the acquisition of 3,605 common shares at $0. On November 3, 2025, he sold 1,303 shares at $6.49 under a Rule 10b5-1 plan as a sell-to-cover for tax withholding tied to the RSU vesting. Following these transactions, he beneficially owns 77,298 shares.

Precision BioSciences (DTIL) reported an insider transaction by General Counsel and Secretary Dario Scimeca on a Form 4. On November 2, 2025, 1,835 RSUs vested (code M) and converted into common stock at $0. On November 3, 2025, 665 shares were sold at $6.49 in a sell-to-cover for taxes under a Rule 10b5-1 plan adopted September 29, 2025. Following these transactions, the reporting person beneficially owned 28,258 shares directly. The holdings figure includes 2,088 shares acquired via the 2019 ESPP at a weighted average price of $4.26.

Precision BioSciences (DTIL) reported an insider equity transaction by President & CEO and Director Michael Amoroso. On November 2, 2025, 9,444 RSUs vested and settled into common stock at $0 per unit, reflecting standard RSU settlement mechanics.

On November 3, 2025, Amoroso sold 3,409 shares at $6.49 per share under a Rule 10b5-1 plan adopted on August 2, 2024. The filing states this was a sell-to-cover transaction to satisfy tax withholding tied to the RSU vesting. Following these transactions, Amoroso beneficially owned 115,575 shares directly. No derivative securities remained after settlement.

Precision BioSciences (DTIL) filed its Q3 2025 10-Q, reporting continued investment in ARCUS gene editing programs and a wider net loss. Quarterly revenue was $13 thousand, reflecting lower billable work under the Novartis collaboration. Operating loss was $20.7 million and net loss was $21.8 million. Cash and cash equivalents were $44.9 million, with restricted cash of $26.3 million; total cash, cash equivalents and restricted cash were $71.2 million as of September 30, 2025.

The balance sheet shows total liabilities of $76.9 million, including a $22.5 million term loan and $26.2 million in deferred revenue, and stockholders’ equity of $16.6 million. A warrant liability was $4.0 million. Shares outstanding were 12,082,665 as of September 30, 2025, and 13,256,751 as of October 29, 2025.

PBGENE-HBV advanced with Cohort 3 dosing in the ELIMINATE-B trial, while PBGENE-DMD moved toward an anticipated U.S. IND filing by year-end 2025 after receiving Rare Pediatric Disease and Orphan Drug designations. Subsequent events included an $8.0 million milestone from Imugene on October 31, 2025 (paid as $3.0 million cash and $5.0 million stock) and Novartis’ notice to terminate the collaboration effective January 30, 2026.